NCT05745805 is a clinical trial of Simultaneous cortico-spinal magnetic resonance imaging, Serum in COVID-19, sponsored by First Affiliated Hospital Xi'an Jiaotong University.

Who is sponsoring NCT05745805?

NCT05745805 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What drugs are being tested in NCT05745805?

Interventions in NCT05745805: Simultaneous cortico-spinal magnetic resonance imaging, Serum.

What condition does NCT05745805 study?

NCT05745805 studies COVID-19, Post-COVID-19 Syndrome, Acute COVID-19, Post-Acute COVID-19.

Is NCT05745805 still recruiting?

NCT05745805 is currently recruiting now. Last updated 27 February 2023.

Last reviewed 2023-02-27 · How we verify

NCT05745805

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cohort Follow-up of Epidemic and Neuroimaging for Patients During the 1st Wave of the COVID-19 in China

Recruiting now Last updated 27 February 2023

What this trial tests

trial testing Simultaneous cortico-spinal magnetic resonance imaging, Serum in COVID-19 in 600 participants. Currently enrolling.

Timeline

12 January 2023

Primary endpoint
12 June 2026

12 September 2026

Quick facts

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	600
Start date	12 January 2023
Primary completion	12 June 2026
Estimated completion	12 September 2026
Sites	1 location across China

Drugs / interventions tested

Simultaneous cortico-spinal magnetic resonance imaging, Serum

Conditions studied

COVID-19 — all drugs for COVID-19 →
Post-COVID-19 Syndrome — all drugs for Post-COVID-19 Syndrome →
Acute COVID-19 — all drugs for Acute COVID-19 →
Post-Acute COVID-19 — all drugs for Post-Acute COVID-19 →

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Who can join

Adults 18 to 65, any sex, with COVID-19 or Post-COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our main objective is to analyze the development of physical impact, mental health and blood profile over follow-up time during the 1st wave of the COVID-19. Besides, we aim to establish a database of post-COVID-19 based on simultaneous cortico-spinal magnetic resonance imaging data to identify high-risk patients with long COVID and prevent the neurological symptoms evolution, optimize the tactics of management in China.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Multicentre, multitime, multidimension, prospective follow-up cohort study on patients during the first wave of COVID-19 in China: a study protocol.
Wu S, Luo Z, Liu H, Zhu J, et al · · 2025 · cited 1× · PMID 39843379 · DOI 10.1136/bmjopen-2023-083023
Acute inflammation and fronto-striatal connectivity in the transition from acute to persistent fatigue after mild COVID-19: A longitudinal fMRI study.
Zhu Q, Lu T, Yuan H, Zhu Y, et al · · 2026 · PMID 41737723 · DOI 10.1016/j.bbih.2026.101196
Segregation and integration of resting-state brain networks in a longitudinal long COVID cohort.
Zhang Y, Ye G, Zeng W, Zhu R, et al · · 2025 · PMID 40230529 · DOI 10.1016/j.isci.2025.112237

Verify or expand the search:

Other trials of Simultaneous cortico-spinal magnetic resonance imaging, Serum

Trials testing the same drug.

NCT06228196 — Cohort Study of Clinical and Neuroimaging Characteristics for BPPV Patients in China · recruiting

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other First Affiliated Hospital Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05745805 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
Last refreshed: 27 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05745805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing